Stefania Mondello

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6504856/publications.pdf

Version: 2024-02-01

211 papers	30,066 citations	31976 53 h-index	6300 158 g-index
216 all docs	216 docs citations	216 times ranked	31639 citing authors

#	Article	IF	Citations
1	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	13.7	7,664
2	Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1223-1249.	13.7	3,928
3	Global, regional, and national burden of neurological disorders, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	10.2	2,625
4	Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurology, The, 2017, 16, 987-1048.	10.2	1,571
5	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 88-106.	10.2	1,512
6	Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health, The, 2022, 7, e105-e125.	10.0	1,199
7	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 56-87.	10.2	1,064
8	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950â€“2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1160-1203.	13.7	890
9	Living systematic review: 1. Introductionâ€”the why, what, when, and how. Journal of Clinical Epidemiology, 2017, 91, 23-30.	5.0	406
10	Five insights from the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1135-1159.	13.7	335
11	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1250-1284.	13.7	330
12	Elevated Levels of Serum Glial Fibrillary Acidic Protein Breakdown Products in Mild and Moderate Traumatic Brain Injury Are Associated With Intracranial Lesions and Neurosurgical Intervention. Annals of Emergency Medicine, 2012, 59, 471-483.	0.6	282
13	Thalamic and Subthalamic Deep Brain Stimulation for Essential Tremor. Neurosurgery, 2012, 70, 840-846.	1.1	264
14	Living systematic reviews: 2. Combining human and machine effort. Journal of Clinical Epidemiology, 2017, 91, 31-37.	5.0	246
15	Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. Lancet, The, 2021, 398, 870-905.	13.7	229
16	Biokinetic Analysis of Ubiquitin C-Terminal Hydrolase-L1 (UCH-L1) in Severe Traumatic Brain Injury Patient Biofluids. Journal of Neurotrauma, 2011, 28, 861-870.	3.4	205
17	Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. Journal of Trauma, 2012, 72, 1335-1344.	2.3	196
18	Î±II-Spectrin Breakdown Products (SBDPs): Diagnosis and Outcome in Severe Traumatic Brain Injury Patients. Journal of Neurotrauma, 2010, 27, 1203-1213.	3.4	193

#	Article	IF	Citations
19	Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review. Frontiers in Neurology, 2017, 8, 300.	2.4	185
20	Living systematic reviews: 4. Living guideline recommendations. Journal of Clinical Epidemiology, 2017, 91, 47-53.	5.0	184
21	Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Critical Care, 2011, 15, R156.	5.8	181
22	Occult hepatitis B virus in liver tissue of individuals without hepatic disease. Journal of Hepatology, 2008, 48, 743-746.	3.7	171
23	Blood-based diagnostics of traumatic brain injuries. Expert Review of Molecular Diagnostics, 2011, 11, 65-78.	3.1	155
24	Human Traumatic Brain Injury Induces Autoantibody Response against Glial Fibrillary Acidic Protein and Its Breakdown Products. PLoS ONE, 2014, 9, e92698.	2.5	149
25	Blood biomarkers on admission in acute traumatic brain injury: Relations to severity, CT findings and care path in the CENTER-TBI study. EBioMedicine, 2020, 56, 102785.	6.1	147
26	Brain Injury Biomarkers May Improve the Predictive Power of the IMPACT Outcome Calculator. Journal of Neurotrauma, 2012, 29, 1770-1778.	3.4	132
27	Glial Neuronal Ratio: A Novel Index for Differentiating Injury Type in Patients with Severe Traumatic Brain Injury. Journal of Neurotrauma, 2012, 29, 1096-1104.	3.4	121
28	Utility of neuron-specific enolase in traumatic brain injury; relations to S100B levels, outcome, and extracranial injury severity. Critical Care, 2016, 20, 285.	5.8	116
29	Mesenchymal Stem Cells in the Treatment of Traumatic Brain Injury. Frontiers in Neurology, 2017, 8, 28.	2.4	113
30	Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI. Neurology, 2018, 91, e1385-e1389.	1.1	110
31	Blood-Based Protein Biomarkers for the Management of Traumatic Brain Injuries in Adults Presenting to Emergency Departments with Mild Brain Injury: A Living Systematic Review and Meta-Analysis. Journal of Neurotrauma, 2021, 38, 1086-1106.	3.4	104
32	Living systematic reviews: 3. Statistical methods for updating meta-analyses. Journal of Clinical Epidemiology, 2017, 91, 38-46.	5.0	102
33	Acute Diagnostic Biomarkers for Spinal Cord Injury: Review of the Literature and Preliminary Research Report. World Neurosurgery, 2015, 83, 867-878.	1.3	91
34	The Challenge of Mild Traumatic Brain Injury: Role of Biochemical Markers in Diagnosis of Brain Damage. Medicinal Research Reviews, 2014, 34, 503-531.	10.5	86
35	Risk of stroke in hospitalized SARS-CoV-2 infected patients: A multinational study. EBioMedicine, 2020, 59, 102939.	6.1	82
36	Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients. Scientific Reports, 2016, 6, 24588.	3.3	81

#	Article	IF	Citations
37	CSF and Plasma Amyloid-Î² Temporal Profiles and Relationships with Neurological Status and Mortality after Severe Traumatic Brain Injury. Scientific Reports, 2014, 4, 6446.	3.3	80
38	Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury. Scientific Reports, 2016, 6, 28203.	3.3	80
39	Combining Biochemical and Imaging Markers to Improve Diagnosis and Characterization of Mild Traumatic Brain Injury in the Acute Setting: Results from a Pilot Study. PLoS ONE, 2013, 8, e80296.	2.5	79
40	Approach to Modeling, Therapy Evaluation, Drug Selection, and Biomarker Assessments for a Multicenter Pre-Clinical Drug Screening Consortium for Acute Therapies in Severe Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 513-522.	3.4	78
41	Î±-Synuclein in CSF of patients with severe traumatic brain injury. Neurology, 2013, 80, 1662-1668.	1.1	71
42	Insight into Pre-Clinical Models of Traumatic Brain Injury Using Circulating Brain Damage Biomarkers: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 595-605.	3.4	71
43	Generalized versus partial reflex seizures: A review. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 512-520.	2.0	70
44	CSF Î±-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism and Related Disorders, 2014, 20, 382-387.	2.2	68
45	Pre-Clinical Testing of Therapies for Traumatic Brain Injury. Journal of Neurotrauma, 2018, 35, 2737-2754.	3.4	68
46	Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone. Antioxidants, 2020, 9, 943.	5.1	67
47	Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms. Progress in Neurobiology, 2018, 165-167, 26-50.	5.7	65
48	Nicotinamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 523-537.	3.4	63
49	Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. Journal of Neurology, 2015, 262, 968-978.	3.6	61
50	Synthesis of Findings, Current Investigations, and Future Directions: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 606-614.	3.4	61
51	Levetiracetam Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 581-594.	3.4	60
52	Assessing neuro-systemic & behavioral components in the pathophysiology of blast-related brain injury. Frontiers in Neurology, 2013, 4, 186.	2.4	59
53	New astroglial injury-defined biomarkers for neurotrauma assessment. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3278-3299.	4.3	57
54	Ubiquitin Carboxy-Terminal Hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure. BMC Neurology, 2012, 12, 85.	1.8	56

#	Article	IF	Citations
55	Degradation of Î²II-Spectrin Protein by Calpain-2 and Caspase-3 Under Neurotoxic and Traumatic Brain Injury Conditions. Molecular Neurobiology, 2015, 52, 696-709.	4.0	56
56	Characteristics and Impact of U.S. Military Blast-Related Mild Traumatic Brain Injury: A Systematic Review. Frontiers in Neurology, 2020, 11, 559318.	2.4	56
57	Acute Temporal Profiles of Serum Levels of UCH-L1 and GFAP and Relationships to Neuronal and Astroglial Pathology following Traumatic Brain Injury in Rats. Journal of Neurotrauma, 2015, 32, 1179-1189.	3.4	55
58	Italy's health performance, 1990â€“2017: findings from the Global Burden of Disease Study 2017. Lancet Public Health, The, 2019, 4, e645-e657.	10.0	54
59	Increased levels of serum MAP-2 at 6-months correlate with improved outcome in survivors of severe traumatic brain injury. Brain Injury, 2012, 26, 1629-1635.	1.2	53
60	Cancer Cachexia Syndrome: Pathogenesis, Diagnosis, and New Therapeutic Options. Nutrition and Cancer, 2015, 67, 12-26.	2.0	53
61	Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12200.	3.7	53
62	Biomarkers Track Damage after Graded Injury Severity in a Rat Model of Penetrating Brain Injury. Journal of Neurotrauma, 2013, 30, 1161-1169.	3.4	51
63	Poorly differentiated clusters (PDCs) as a novel histological predictor of nodal metastases in pT1 colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 655-662.	2.8	51
64	Erythropoietin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 538-552.	3.4	51
65	SARS-CoV-2 and Stroke Characteristics. Stroke, 2021, 52, e117-e130.	2.0	51
66	Anesthetic Techniques and Cancer Recurrence after Surgery. Scientific World Journal, The, 2014, 2014, 1-10.	2.1	50
67	LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-310164.	1.9	50
68	Glutamine treatment attenuates the development of ischaemia/reperfusion injury of the gut. European Journal of Pharmacology, 2010, 643, 304-315.	3.5	48
69	Sexâ€Related Differences in the Effects of Sportsâ€Related Concussion: A Review. Journal of Neuroimaging, 2020, 30, 387-409.	2.0	48
70	Circulating Brain Injury Exosomal Proteins following Moderate-to-Severe Traumatic Brain Injury: Temporal Profile, Outcome Prediction and Therapy Implications. Cells, 2020, 9, 977.	4.1	48
71	Burden of non-communicable diseases among adolescents aged 10â€“24 years in the EU, 1990â€“2019: a systematic analysis of the Global Burden of Diseases Study 2019. The Lancet Child and Adolescent Health, 2022, 6, 367-383.	5.6	48
72	Emerging markers of cachexia predict survival in cancer patients. BMC Cancer, 2014, 14, 828.	2.6	44

#	Article	IF	Citations
73	Cyclosporine Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 553-566.	3.4	44
74	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i12-i26.	2.4	44
75	Neuroprotective effect of preoperatively induced mild hypothermia as determined by biomarkers and histopathological estimation in a rat subdural hematoma decompression model. Journal of Neurosurgery, 2013, 118, 370-380.	1.6	43
76	Multi-Center Pre-clinical Consortia to Enhance Translation of Therapies and Biomarkers for Traumatic Brain Injury: Operation Brain Trauma Therapy and Beyond. Frontiers in Neurology, 2018, 9, 640.	2.4	42
77	Systems Biology, Bioinformatics, and Biomarkers in Neuropsychiatry. Frontiers in Neuroscience, 2012, 6, 187.	2.8	41
78	Operation Brain Trauma Therapy: 2016 Update. Military Medicine, 2018, 183, 303-312.	0.8	41
79	Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma. Electrophoresis, 2012, 33, 3659-3668.	2.4	40
80	Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: A comparison with n-acetylcysteine. European Journal of Pharmacology, 2012, 674, 397-406.	3.5	40
81	Clinical and pathophysiological clues of respiratory dysfunction in late-onset Pompe disease: New insights from a comparative study by MRI and respiratory function assessment. Neuromuscular Disorders, 2015, 25, 852-858.	0.6	40
82	Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 567-580.	3.4	40
83	MSâ€based glycomics and glycoproteomics methods enabling isomeric characterization. Mass Spectrometry Reviews, 2023, 42, 577-616.	5.4	40
84	Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2. Journal of Neurology, 2017, 264, 2472-2480.	3.6	38
85	Psoriasis and Cardiovascular Risk: Correlation Between Psoriasis and Cardiovascular Functional Indices. Angiology, 2018, 69, 31-37.	1.8	38
86	An updated overview of animal models in neuropsychiatry. Neuroscience, 2013, 240, 204-218.	2.3	36
87	A Direct Cortico-Nigral Pathway as Revealed by Constrained Spherical Deconvolution Tractography in Humans. Frontiers in Human Neuroscience, 2016, 10, 374.	2.0	36
88	Combination of drug and stem cells neurotherapy: Potential interventions in neurotrauma and traumatic brain injury. Neuropharmacology, 2019, 145, 177-198.	4.1	36
89	Biofluid Proteomics and Biomarkers in Traumatic Brain Injury. Methods in Molecular Biology, 2017, 1598, 45-63.	0.9	34
90	Extracellular vesicles: pathogenetic, diagnostic and therapeutic value in traumatic brain injury. Expert Review of Proteomics, 2018, 15, 451-461.	3.0	34

#	Article	IF	Citations
91	Melatonin Therapy Modulates Cerebral Metabolism and Enhances Remyelination by Increasing PDK4 in a Mouse Model of Multiple Sclerosis. Frontiers in Pharmacology, 2019, 10, 147.	3.5	34
92	Cerebrospinal Fluid Protein Biomarker Panel for Assessment of Neurotoxicity Induced by Kainic Acid in Rats. Toxicological Sciences, 2012, 130, 158-167.	3.1	33
93	<scp>ENIGMA</scp> brain injury: Framework, challenges, and opportunities. Human Brain Mapping, 2022, 43, 149-166.	3.6	33
94	Autoantibodies in traumatic brain injury and central nervous system trauma. Neuroscience, 2014, 281, 16-23.	2.3	32
95	Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD). Journal of Inherited Metabolic Disease, 2016, 39, 391-398.	3.6	32
96	Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study. Neuromuscular Disorders, 2016, 26, 189-196.	0.6	32
97	Circulating GFAP and Iba-1 levels are associated with pathophysiological sequelae in the thalamus in a pig model of mild TBI. Scientific Reports, 2020, 10, 13369.	3.3	32
98	Glial fibrillary acidic protein for the early diagnosis of intracerebral hemorrhage: Systematic review and meta-analysis of diagnostic test accuracy. International Journal of Stroke, 2019, 14, 390-399.	5.9	31
99	Advances in Cardiovascular Biomarker Discovery. Biomedicines, 2020, 8, 552.	3.2	31
100	A neuroproteomic and systems biology analysis of rat brain post intracerebral hemorrhagic stroke. Brain Research Bulletin, 2014, 102, 46-56.	3.0	30
101	Exploratory study of serum ubiquitin carboxyl-terminal esterase L1 and glial fibrillary acidic protein for outcome prognostication after pediatric cardiac arrest. Resuscitation, 2016, 101, 65-70.	3.0	30
102	Perceived Stress in a Gender Perspective: A Survey in a Population of Unemployed Subjects of Southern Italy. Frontiers in Public Health, 2021, 9, 640454.	2.7	30
103	Complications of Trauma Patients Admitted to the ICU in Level I Academic Trauma Centers in the United States. BioMed Research International, 2014, 2014, 1-7.	1.9	29
104	Beirut Ammonium Nitrate Blast: Analysis, Review, and Recommendations. Frontiers in Public Health, 2021, 9, 657996.	2.7	29
105	Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk. CNS and Neurological Disorders - Drug Targets, 2016, 15, 1030-1044.	1.4	29
106	Cerebrospinal Fluid Biomarker Candidates for Parkinsonian Disorders. Frontiers in Neurology, 2012, 3, 187.	2.4	28
107	Neurological and Neuropsychological Changes Associated with SARS-CoV-2 Infection: New Observations, New Mechanisms. Neuroscientist, 2022, 28, 552-571.	3.5	28
108	Genotoxic effects of anesthetic agents: an update. Expert Opinion on Drug Safety, 2011, 10, 891-899.	2.4	27

#	Article	IF	Citations
109	Docosahexaenoic acid (DHA) enhances the therapeutic potential of neonatal neural stem cell transplantation postâ€"Traumatic brain injury. Behavioural Brain Research, 2018, 340, 1-13.	2.2	27
110	Different expression of ubiquitin C-terminal hydrolase-L1 and Î±II-spectrin in ischemic and hemorrhagic stroke: Potential biomarkers in diagnosis. Brain Research, 2013, 1540, 84-91.	2.2	26
111	Neuroproteomics and Systems Biology Approach to Identify Temporal Biomarker Changes Post Experimental Traumatic Brain Injury in Rats. Frontiers in Neurology, 2016, 7, 198.	2.4	26
112	Epidemiology and clinical characteristics of traumatic brain injury in Lebanon. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	1.0	26
113	Novel biomarker signatures for idiopathic REM sleep behavior disorder. Neurology, 2018, 91, e1710-e1715.	1.1	26
114	Serum-Based Phospho-Neurofilament-Heavy Protein as Theranostic Biomarker in Three Models of Traumatic Brain Injury: An Operation Brain Trauma Therapy Study. Journal of Neurotrauma, 2019, 36, 348-359.	3.4	26
115	Protein Biomarkers for Traumatic and Ischemic Brain Injury: From Bench to Bedside. Translational Stroke Research, 2011, 2, 455-462.	4.2	25
116	Post-Genomics Nanotechnology Is Gaining Momentum: Nanoproteomics and Applications in Life Sciences. OMICS A Journal of Integrative Biology, 2014, 18, 111-131.	2.0	25
117	Biomarkers. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 127, 245-265.	1.8	25
118	GFAP and S100B: What You Always Wanted to Know and Never Dared to Ask. Frontiers in Neurology, 2022, 13, 835597.	2.4	25
119	Imaging as a biomarker in drug discovery for Alzheimerâ€™s disease: is MRI a suitable technology?. Alzheimer's Research and Therapy, 2014, 6, 51.	6.2	24
120	Deciphering glycomics and neuroproteomic alterations in experimental traumatic brain injury: Comparative analysis of aspirin and clopidogrel treatment. Electrophoresis, 2016, 37, 1562-1576.	2.4	24
121	Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical Trial. Critical Care Medicine, 2018, 46, 554-561.	0.9	24
122	The Burden of Dementia due to Down Syndrome, Parkinsonâ€™s Disease, Stroke, and Traumatic Brain Injury: A Systematic Analysis for the Global Burden of Disease Study 2019. Neuroepidemiology, 2021, 55, 286-296.	2.3	24
123	Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients. Nutrition, 2010, 26, 677-681.	2.4	23
124	p-CREB expression in human gliomas: potential use in the differential diagnosis between astrocytoma and oligodendroglioma. Human Pathology, 2015, 46, 231-238.	2.0	23
125	Delayed sleep phase syndrome and bipolar disorder: Pathogenesis and available common biomarkers. Sleep Medicine Reviews, 2018, 41, 133-140.	8.5	23
126	Subdural hematoma decompression model: A model of traumatic brain injury with ischemic-reperfusional pathophysiology: A review of the literature. Behavioural Brain Research, 2018, 340, 23-28.	2.2	23

#	Article	IF	Citations
127	Effects of shortâ€toâ€long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). Neuropathology and Applied Neurobiology, 2018, 44, 449-462.	3.2	23
128	Night shift work in resident physicians: does it affect mood states and cognitive levels?. Journal of Affective Disorders, 2020, 272, 289-294.	4.1	23
129	Biomarkers for Traumatic Brain Injury: Data Standards and Statistical Considerations. Journal of Neurotrauma, 2021, 38, 2514-2529.	3.4	23
130	Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2011, 383, 493-508.	3.0	22
131	High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer. Technology in Cancer Research and Treatment, 2016, 15, 179-185.	1.9	21
132	Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019. Journal of Neurology, 2022, 269, 2080-2098.	3.6	21
133	Glibenclamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2021, 38, 628-645.	3.4	20
134	THALIDOMIDE SUPPRESSES SCLEROSING ENCAPSULATING PERITONITIS IN A RAT EXPERIMENTAL MODEL. Shock, 2009, 32, 332-339.	2.1	19
135	Blood-based traumatic brain injury biomarkers â€“ Clinical utilities and regulatory pathways in the United States, Europe and Canada. Expert Review of Molecular Diagnostics, 2021, 21, 1303-1321.	3.1	19
136	Exploring serum glycome patterns after moderate to severe traumatic brain injury: A prospective pilot study. EClinicalMedicine, 2022, 50, 101494.	7.1	18
137	Nanotheragnostic Applications for Ischemic and Hemorrhagic Strokes: Improved Delivery for a Better Prognosis. Current Neurology and Neuroscience Reports, 2015, 15, 505.	4.2	17
138	LCâ€“MS/MS glycomics of idiopathic rapid eye movement sleep behavior disorder. Electrophoresis, 2018, 39, 3096-3103.	2.4	17
139	Biomarkers in psychiatry: how close are we?. Frontiers in Psychiatry, 2012, 3, 114.	2.6	16
140	Sex Differences in Circulating T-Tau Trajectories After Sports-Concussion and Correlation With Outcome. Frontiers in Neurology, 2020, 11, 651.	2.4	16
141	Toward a global and reproducible science for brain imaging in neurotrauma: the ENIGMA adult moderate/severe traumatic brain injury working group. Brain Imaging and Behavior, 2021, 15, 526-554.	2.1	16
142	Erythropoietin suppresses peritoneal fibrosis in rat experimental model. European Journal of Pharmacology, 2009, 604, 138-149.	3.5	15
143	Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury. Current Medicinal Chemistry, 2021, 28, 2369-2391.	2.4	15
144	Proteomics studies in inner ear disorders: pathophysiology and biomarkers. Expert Review of Proteomics, 2015, 12, 185-196.	3.0	14

#	Article	IF	Citations
145	Translating Biomarkers Research to Clinical Care: Applications and Issues for Rehabilomics. PM and R, 2011, 3, S31-8.	1.6	13
146	Glial fibrillary acidic protein: A promising biomarker in pediatric brain injury*. Pediatric Critical Care Medicine, 2011, 12, 603-604.	0.5	13
147	Three-dimensional treatment planning for vaginal cuff brachytherapy: Dosimetric effects on organs at risk according to patients position. Brachytherapy, 2014, 13, 568-571.	0.5	13
148	The currency, completeness and quality of systematic reviews of acute management of moderate to severe traumatic brain injury: A comprehensive evidence map. PLoS ONE, 2018, 13, e0198676.	2.5	13
149	Glycomic and Glycoproteomic Techniques in Neurodegenerative Disorders and Neurotrauma: Towards Personalized Markers. Cells, 2022, 11, 581.	4.1	13
150	Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. SpringerPlus, 2014, 3, 123.	1.2	12
151	Quantitative pupillometry and neuron-specific enolase independently predict return of spontaneous circulation following cardiogenic out-of-hospital cardiac arrest: a prospective pilot study. Scientific Reports, 2018, 8, 15964.	3.3	12
152	Purkinje cell COX deficiency and mtDNA depletion in an animal model of spinocerebellar ataxia type 1. Journal of Neuroscience Research, 2018, 96, 1576-1585.	2.9	12
153	Protein Degradome of Spinal Cord Injury: Biomarkers and Potential Therapeutic Targets. Molecular Neurobiology, 2020, 57, 2702-2726.	4.0	12
154	Blood Biomarkers and Structural Imaging Correlations Post-Traumatic Brain Injury: A Systematic Review. Neurosurgery, 2022, 90, 170-179.	1.1	12
155	Prognostic factors in patients treated with stereotactic image-guided robotic radiosurgery for brain metastases: a single-center retrospective analysis of 223 patients. Neurosurgical Review, 2016, 39, 495-504.	2.4	11
156	Cerebrospinal fluid levels of GFAP and pNF-H are elevated in patients with chronic spinal cord injury and neurological deterioration. Acta Neurochirurgica, 2020, 162, 2075-2086.	1.7	11
157	Muscle histological changes in a large cohort of patients affected with Becker muscular dystrophy. Acta Neuropathologica Communications, 2022, 10, 48.	5.2	11
158	Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice. European Journal of Pharmacology, 2011, 658, 28-40.	3.5	10
159	Psychogenic Itch Responding to Topiramate. Psychosomatics, 2013, 54, 297-300.	2.5	10
160	Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research. Expert Review of Proteomics, 2015, 12, 637-650.	3.0	10
161	Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain Injury. Neuroscientist, 2021, 27, 620-649.	3.5	10
162	Serum Glycomics Profiling of Patients with Primary Restless Legs Syndrome Using LCâ€“MS/MS. Journal of Proteome Research, 2020, 19, 2933-2941.	3.7	10

#	Article	IF	Citations
163	Characterization of Traumatic Brain Injury Research in the Middle East and North Africa Region: A Systematic Review. Neuroepidemiology, 2021, 55, 20-31.	2.3	10
164	Discriminative value of glial fibrillar acidic protein (GFAP) as a diagnostic tool in acute stroke. Individual patient data meta-analysis. Journal of Investigative Medicine, 2020, 68, 1379-1385.	1.6	10
165	Fast Magnetic Resonance Enterography Protocol for the Evaluation of Patients with Crohnâ€™s Disease: A Pilot Study. Journal of Clinical Imaging Science, 2020, 10, 25.	1.1	10
166	Mitoquinone supplementation alleviates oxidative stress and pathologic outcomes following repetitive mild traumatic brain injury at a chronic time point. Experimental Neurology, 2022, 351, 113987.	4.1	10
167	Role of Systems Biology in Brain Injury Biomarker Discovery: Neuroproteomics Application. Methods in Molecular Biology, 2016, 1462, 157-174.	0.9	9
168	Searching for Novel Candidate Biomarkers of RLS in Blood by Proteomic Analysis. Nature and Science of Sleep, 2021, Volume 13, 873-883.	2.7	9
169	Operation Brain Trauma Therapy: An Exploratory Study of Levetiracetam Treatment Following Mild Traumatic Brain Injury in the Micro Pig. Frontiers in Neurology, 2020, 11, 586958.	2.4	9
170	Minor and Repetitive Head Injury. Advances and Technical Standards in Neurosurgery, 2015, 42, 147-192.	0.5	9
171	Preoperative-Induced Mild Hypothermia Attenuates Neuronal Damage in a Rat Subdural Hematoma Model. Acta Neurochirurgica Supplementum, 2013, 118, 77-81.	1.0	9
172	Thyroid Hormone Autoantibodies: Are They a Better Marker to Detect Early Thyroid Damage in Patients with Hematologic Cancers Receiving Tyrosine Kinase Inhibitor or Immunoregulatory Drug Treatments?. Current Oncology, 2016, 23, 165-170.	2.2	8
173	Burden of non-communicable disease studies in Europe: a systematic review of data sources and methodological choices. European Journal of Public Health, 2022, 32, 289-296.	0.3	8
174	Genotoxic effects of anesthetic agents. Expert Opinion on Drug Safety, 2008, 7, 447-458.	2.4	7
175	Hypophosphatemia as Unusual Cause of ARDS in Cushingâ€™s Syndrome Secondary to Ectopic CRH Production. A Case Report. Scientific World Journal, The, 2008, 8, 138-144.	2.1	7
176	Characterization of the Kallikrein-Kinin System Post Chemical Neuronal Injury: An In Vitro Biochemical and Neuroproteomics Assessment. PLoS ONE, 2015, 10, e0128601.	2.5	7
177	Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onset Pompe Disease (LOPD). Frontiers in Neurology, 2018, 9, 880.	2.4	7
178	Abstract P81: SARS-CoV-2 and Stroke Characteristics a Report From the Multinational COVID-19 Stroke Study Group. Stroke, 2021, 52, .	2.0	7
179	Neutrophil gelatinase-associated lipocalin in peritoneal dialysis reflects status of peritoneum. Journal of Nephrology, 2013, 26, 1151-1159.	2.0	7
180	Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimerâ€™s Disease Patients. Cells, 2022, 11, 163.	4.1	7

#	Article	IF	Citations
181	Renal Complications in Oncohematologic Patients. Journal of Investigative Medicine, 2009, 57, 892-901.	1.6	6
182	Editorial: Biomarkers in Neurology. Frontiers in Neurology, 2020, 11, 190.	2.4	6
183	Hormones in experimental autoimmune encephalomyelitis (EAE) animal models. Translational Neuroscience, 2021, 12, 164-189.	1.4	6
184	Effects of sport-related repetitive subconcussive head impacts on biofluid markers: a scoping review protocol. BMJ Open, 2021, 11, e046452.	1.9	6
185	H1299R Variant in Factor V and Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis Protocol. Genes, 2022, 13, 1019.	2.4	6
186	Editorial: Developing Successful Neuroprotective Treatments for TBI: Translational Approaches, Novel Directions, Opportunities and Challenges. Frontiers in Neurology, 2019, 10, 1326.	2.4	5
187	Kollidon VA64 Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2021, 38, 2454-2472.	3.4	5
188	Microvascular imaging ultrasound (MicroV) and power Doppler vascularization analysis in a pediatric population with early scrotal pain onset. Japanese Journal of Radiology, 2022, 40, 192-201.	2.4	5
189	Angiotensin receptor antagonists. Critical Care Medicine, 2012, 40, 1023-1024.	0.9	4
190	Developing a molecular taxonomy for traumatic brain injury: a perspective to enable the development of diagnostics and therapeutics. Biomarkers in Medicine, 2015, 9, 619-621.	1.4	4
191	Abstract P88: Risk of Stroke in Hospitalized SARS-Cov-2 Infected Patients a Multinational Population-Based Study. Stroke, 2021, 52, .	2.0	4
192	Bioinformatics Approach to Understanding Interacting Pathways in Neuropsychiatric Disorders. Methods in Molecular Biology, 2014, 1168, 157-172.	0.9	4
193	The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012, 6, 235-250.	0.6	3
194	Ketotifen-induced nocturnal bruxism. European Journal of Pediatrics, 2014, 173, 1585-1586.	2.7	3
195	Thyroxine transfer from cerebrospinal fluid into choroid plexus and brain is affected by brefeldin A, low sodium, BCH, and phloretin, in ventriculo-cisternal perfused rabbits. Frontiers in Cell and Developmental Biology, 2015, 3, 60.	3.7	3
196	Data comparison between pharmacological induction of labour and spontaneous delivery. A single centre experience. Ginekologia Polska, 2016, 87, 697-700.	0.7	3
197	Family, lifestyles and new and old type of smoking in young adults: insights from an italian multiple-center study. Annali Di Igiene: Medicina Preventiva E Di Comunita, 2021, 33, 131-140.	0.7	2
198	Brain Injury Markers: Where are We?. Frontiers in Neurology, 2014, 5, 145.	2.4	1

#	Article	IF	Citations
199	Rodent Models of Methamphetamine Misuse: Mechanisms of Methamphetamine Action and Comparison of Different Rodent Paradigms. Methods in Molecular Biology, 2019, 2011, 221-250.	0.9	1
200	Risk of Cerebrovascular Events in Hospitalized Patients with SARS-CoV-2 Infection. SSRN Electronic Journal, 0, , .	0.4	1
201	Clinical usefulness of anti-muscarinic type 3 receptor autoantibodies in patients with primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 795-803.	0.8	1
202	The effect of clopidogrel and aspirin on the severity of traumatic brain injury in a rat model. Neurochemistry International, 2022, 154, 105301.	3.8	1
203	Cerebrospinal fluid biomarkers of white matter injury and astrogliosis are associated with the severity and surgical outcome of degenerative cervical spondylotic myelopathy. Spine Journal, 2022, 22, 1848-1856.	1.3	1
204	Stefania Mondello. Nature, 2010, 466, 1009-1009.	27.8	0
205	8 Years of Experience with Alglucosidase Alpha Treatment: Facts and Perspectives. Journal of Neuromuscular Diseases, 2015, 2, S4-S4.	2.6	0
206	Utilities of TBI Biomarkers in Various Clinical Settings. RSC Drug Discovery Series, 2012, , 184-199.	0.3	0
207	Data Mining Strategies Applied in Brain Injury Models. Springer Optimization and Its Applications, 2012, , 1-13.	0.9	0
208	Blood Biomarkers for Acute CNS Insults: Traumatic Brain Injury and Stroke. , 2014, , 303-331.		0
209	Sleep After Traumatic Brain Injury. , 2021, , 255-268.		0
210	Exploring the evidence for the effectiveness of health interventions for COVID-19 targeting migrants: a systematic review protocol. BMJ Open, 2021, 11, e057985.	1.9	0
211	Brain injury biomarkers: Proteins and autoantibodies interplay. , 2022, , 239-250.		0